123 related articles for article (PubMed ID: 3140691)
1. Is the metabolism of alfentanil subject to debrisoquine polymorphism? A study using human liver microsomes.
Lavrijsen KL; Van Houdt JM; Van Dyck DM; Hendrickx JJ; Woestenborghs RJ; Lauwers W; Meuldermans WE; Heykants JJ
Anesthesiology; 1988 Oct; 69(4):535-40. PubMed ID: 3140691
[TBL] [Abstract][Full Text] [Related]
2. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
3. Oxidation of tricyclic antidepressant drugs, debrisoquine and 7-ethoxyresorufin, by human liver preparations.
von Bahr C; Birgersson C; Morgan ET; Eriksson O; Göransson M; Spina E; Woodhouse K
Xenobiotica; 1986 May; 16(5):391-400. PubMed ID: 3739365
[TBL] [Abstract][Full Text] [Related]
4. Substrate specificity of the form of cytochrome P-450 catalyzing the 4-hydroxylation of debrisoquine in man.
Boobis AR; Murray S; Kahn GC; Robertz GM; Davies DS
Mol Pharmacol; 1983 Mar; 23(2):474-81. PubMed ID: 6220203
[TBL] [Abstract][Full Text] [Related]
5. Enzymatic basis of the debrisoquine/sparteine-type genetic polymorphism of drug oxidation. Characterization of bufuralol 1'-hydroxylation in liver microsomes of in vivo phenotyped carriers of the genetic deficiency.
Dayer P; Kronbach T; Eichelbaum M; Meyer UA
Biochem Pharmacol; 1987 Dec; 36(23):4145-52. PubMed ID: 3689440
[TBL] [Abstract][Full Text] [Related]
6. Influence of the genetically controlled deficiency in debrisoquine hydroxylation on antipyrine metabolite formation.
Danhof M; Idle JR; Teunissen MW; Sloan TP; Breimer DD; Smith RL
Pharmacology; 1981; 22(6):349-58. PubMed ID: 7267701
[TBL] [Abstract][Full Text] [Related]
7. In vitro evidence against the oxidation of quinidine by the sparteine/debrisoquine monooxygenase of human liver.
Otton SV; Brinn RU; Gram LF
Drug Metab Dispos; 1988; 16(1):15-7. PubMed ID: 2894945
[TBL] [Abstract][Full Text] [Related]
8. Bufuralol metabolism in human liver: a sensitive probe for the debrisoquine-type polymorphism of drug oxidation.
Minder EI; Meier PJ; Müller HK; Minder C; Meyer UA
Eur J Clin Invest; 1984 Jun; 14(3):184-9. PubMed ID: 6147254
[TBL] [Abstract][Full Text] [Related]
9. Alfentanil pharmacokinetics and metabolism in humans.
Meuldermans W; Van Peer A; Hendrickx J; Woestenborghs R; Lauwers W; Heykants J; Vanden Bussche G; Van Craeyvelt H; Van der Aa P
Anesthesiology; 1988 Oct; 69(4):527-34. PubMed ID: 3140690
[TBL] [Abstract][Full Text] [Related]
10. Identification of the pharmacogenetic determinants of alfentanil metabolism: cytochrome P-450 3A4. An explanation of the variable elimination clearance.
Yun CH; Wood M; Wood AJ; Guengerich FP
Anesthesiology; 1992 Sep; 77(3):467-74. PubMed ID: 1519785
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation of sufentanil in liver microsomes of rats, dogs, and humans.
Lavrijsen K; Van Houdt J; Van Dyck D; Hendrickx J; Lauwers W; Hurkmans R; Bockx M; Janssen C; Meuldermans W; Heykants J
Drug Metab Dispos; 1990; 18(5):704-10. PubMed ID: 1981724
[TBL] [Abstract][Full Text] [Related]
12. Comparative metabolism of debrisoquine, 7-ethoxyresorufin and benzo(a)pyrene in liver microsomes from humans, and from rats treated with cytochrome P-450 inducers.
Birgersson C; Blanck A; Woodhouse K; Mellström B; von Bahr C
Acta Pharmacol Toxicol (Copenh); 1985 Aug; 57(2):117-20. PubMed ID: 4061088
[TBL] [Abstract][Full Text] [Related]
13. Relationship of N-demethylation of amiflamine and its metabolite to debrisoquine hydroxylation polymorphism.
Alván G; Grind M; Graffner C; Sjöqvist F
Clin Pharmacol Ther; 1984 Oct; 36(4):515-9. PubMed ID: 6478737
[TBL] [Abstract][Full Text] [Related]
14. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
15. Debrisoquine-type polymorphism of drug oxidation: purification from human liver of a cytochrome P450 isozyme with high activity for bufuralol hydroxylation.
Gut J; Gasser R; Dayer P; Kronbach T; Catin T; Meyer UA
FEBS Lett; 1984 Aug; 173(2):287-90. PubMed ID: 6146537
[TBL] [Abstract][Full Text] [Related]
16. Hepatic monooxygenase activities in subjects with a genetic defect in drug oxidation.
Meier PJ; Mueller HK; Dick B; Meyer UA
Gastroenterology; 1983 Sep; 85(3):682-92. PubMed ID: 6603386
[TBL] [Abstract][Full Text] [Related]
17. Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.
Spina E; Birgersson C; von Bahr C; Ericsson O; Mellström B; Steiner E; Sjöqvist F
Clin Pharmacol Ther; 1984 Nov; 36(5):677-82. PubMed ID: 6488689
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a human liver cytochrome P-450 involved in the oxidation of debrisoquine and other drugs by using antibodies raised to the analogous rat enzyme.
Distlerath LM; Guengerich FP
Proc Natl Acad Sci U S A; 1984 Dec; 81(23):7348-52. PubMed ID: 6594694
[TBL] [Abstract][Full Text] [Related]
19. Metoprolol oxidation by rat liver microsomes. Inhibition by debrisoquine and other drugs.
Lennard MS; Crewe HK; Tucker GT; Woods HF
Biochem Pharmacol; 1986 Aug; 35(16):2757-61. PubMed ID: 2943287
[TBL] [Abstract][Full Text] [Related]
20. Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine.
Speirs CJ; Murray S; Boobis AR; Seddon CE; Davies DS
Br J Clin Pharmacol; 1986 Dec; 22(6):739-43. PubMed ID: 3567021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
